Abstract

There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21 and M2 (p = 0.03) and between D21 and M3 (p < 0.0001). Here, we report that SARS-CoV-2 can elicit a NAb response correlated with anti-RBD antibody levels. However, this neutralizing activity declines, and may even be lost, in association with a decrease in systemic IgA antibody levels, from two months after disease onset. This short-lasting humoral protection supports strong recommendations to maintain infection prevention and control measures in HCW, and suggests that periodic boosts of SARS-CoV-2 vaccination may be required.

The humoral immune response to SARS-CoV-2 infection is not yet fully understood. Here, Marot et al. monitor the longitudinal profile and neutralizing activity of IgG, IgA, and IgM among 26 healthcare workers and provide evidence for a short-lasting humoral immune protection due to a decrease of neutralizing antibody titers within 3 months.

Details

Title
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
Author
Marot Stéphane 1 ; Malet, Isabelle 1   VIAFID ORCID Logo  ; Leducq Valentin 1 ; Zafilaza, Karen 1 ; Sterlin Delphine 2 ; Planas Delphine 3 ; Gothland Adélie 1 ; Jary Aude 1   VIAFID ORCID Logo  ; Dorgham Karim 2   VIAFID ORCID Logo  ; Bruel Timothée 3   VIAFID ORCID Logo  ; Attali Valérie 4 ; Baresse Isabelle 4 ; Beurton Alexandra 4 ; Boddaert Jacques 4 ; Bourmaleau Julie 4 ; Catala, Martin 4 ; Demoule Alexandre 4 ; Dunoyer Violaine 4 ; Esteban-Amarilla, Cristina 4 ; Hausfater Pierre 4 ; Haziot Noémie 4 ; Ip Queyras 4 ; Kubis Nathalie 4 ; Lhoest, Laurence 4 ; Lubetzki Catherine 4 ; Marion, Fabienne 4 ; Morawiec Elise 4 ; Mourtada Leila 4 ; Orcel Brigitte 4 ; Morelot-Panzini Capucine 4 ; Raux Mathieu 4 ; Reinhard, Christophe 4 ; Riquier Claire 4 ; Roubertier Xavier 4 ; Weiss, Nicolas 4 ; Zalc, Bernard 4 ; Burrel Sonia 1   VIAFID ORCID Logo  ; Boutolleau, David 1 ; Schwartz, Olivier 3 ; Gorochov Guy 2 ; Calvez, Vincent 1 ; Anne-Geneviève, Marcelin 1   VIAFID ORCID Logo 

 Department of Virology, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Paris, France (GRID:grid.462718.e) 
 Department of Immunology, Sorbonne Université, INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP, Pitié Salpêtrière Hospital, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058) 
 Institut Pasteur, Virus and Immunity Unit, Department of Virology, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535); Vaccine Research Institute, Creteil, France (GRID:grid.511001.4) 
 Pitié Salpêtrière Hospital, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2556547125
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.